Please assess the completion status of the following clinical trial:

Trial Title: CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed metastatic pancreatic ductal carcinoma~* One or more metastatic lesions measurable on MRI, PET/CT, or dedicated CT scan according to RECIST v1.1.~* Eligible for treatment with nabpaclitaxel and gemcitabine~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Life expectancy of at least 3 months~* Adequate archival tissue from prior biopsy for biomarker evaluation or willingness to undergo biopsy before treatment starts~* The patient is capable of understanding and complying with the protocol and the subject or, when applicable, the subject's legally acceptable representative has signed the informed consent~* A negative serum pregnancy test (if a premenopausal female patient)~* Acceptable liver function: Bilirubin ≥ 1.5 times upper limit of normal; AST (SGOT) \< 10 times upper limit of normal, ALT (SGPT) and Alkaline phosphatase 2.5 times upper limit of normal (if liver metastases are present, then ≤ 5 x ULN is allowed).~* Acceptable renal function: Serum creatinine within normal limits; calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal by the Cockroft-Gault equation.~* Acceptable hematologic status: Granulocyte ≥ 1500 cells/mm3; Platelet count ≥ 100,000 plt/mm3; Hemoglobin ≥ 9 g/dL.~* Urinalysis: No clinically significant abnormalities.~* Acceptable coagulation status: PT within normal limits; PTT within normal limits.~* For men and women of child-producing potential, the use of effective contraceptive methods during the study.~Exclusion Criteria:~* Prior chemotherapy or any other investigational agents for the treatment of pancreatic cancer.~* Concurrent use of any other anti-cancer therapy, including chemotherapy, targeted therapy, immunotherapy, or biological agents.~* Participants with known brain metastases.~* New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.~* Pregnant or nursing women. Women of child-bearing potential and men must agree to use adequate contraception.~* Unwillingness or inability to comply with procedures required in this protocol.~* Known infection with HIV, hepatitis B, or hepatitis C.~* Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions per physician judgement) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A (Dose Escalation) (Type: EXPERIMENTAL): Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m\^2) / gemcitabine (1000mg/m\^2) combination given on Days 1, 8, 15.
- Part B (Expansion) (Type: EXPERIMENTAL): Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m\^2) and gemcitabine (1000mg/m\^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).